Get started
Author

Daniel Gruener

A phase 1, randomized, placebo-controlled, 3-day, dose-ranging study of GS-5885, an NS5A inhibitor, in patients with genotype 1 hepatitis C
2012 · Eric J. Lawitz, Daniel Gruener, et al. · Journal of Hepatology · 159
Safety and efficacy of pioglitazone for the delay of cognitive impairment in people at risk of Alzheimer's disease (TOMMORROW): a prognostic biomarker study and a phase 3, randomised, double-blind, placebo-controlled trial
2021 · Daniel K Burns, Robert C Alexander, et al. · The Lancet Neurology · 130
Cognitive Therapy with Chronic Pain Patients
2004 · Carrie Winterowd, Aaron T. Beck, et al. · Pain Practice · 79
Evaluation of the Tolerability of Switching Patients on Chronic Full μ-Opioid Agonist Therapy to Buccal Buprenorphine
2016 · Lynn Webster, Daniel Gruener, et al. · Pain Medicine · 32
PDF
Safety, Pharmacokinetics and Pharmacodynamics of the Oral Toll-Like Receptor 7 Agonist GS-9620 in Treatment-Naive Patients with Chronic Hepatitis C
2014 · Eric Lawitz, Daniel Gruener, et al. · Antiviral Therapy · 30
A randomized, double-blind, multiple-dose study of the pan-genotypic NS5A inhibitor samatasvir in patients infected with hepatitis C virus genotype 1, 2, 3 or 4
2014 · Bradley Vince, John M. Hill, et al. · Journal of Hepatology · 25
Correlations of plasma renin activity and aldosterone concentration with ambulatory blood pressure responses to nebivolol and valsartan, alone and in combination, in hypertension
2015 · Thomas D. Giles, George Bakris, et al. · Journal of the American Society of Hypertension · 16
PDF
Proof-of-Mechanism Study of the Phosphodiesterase 10 Inhibitor RG7203 in Patients With Schizophrenia and Negative Symptoms
2021 · Daniel Umbricht, Markus Abt, et al. · Biological Psychiatry Global Open Science · 13
PDF
1188 Gs-6620, a Liver-targeted Nucleotide Prodrug, Exhibits Antiviral Activity and Favorable Safety Profile Over 5 Days in Treatment Naive Chronic Hcv Genotype 1 Subjects
2012 · E. Lawitz, J. Hill, et al. · Journal of Hepatology · 11
1219 Three-day, Dose-ranging Study of the Hcv Ns5a Inhibitor Gs-5885
2011 · E. Lawitz, D. Gruener, et al. · Journal of Hepatology · 11
Sequelae of sexual assault
1997 · Carla Rodgers, Daniel Gruener · Primary Care Update for OB/GYNS · 11
Clinical Outcomes from an Open-Label Study of Edivoxetine Use in Pediatric Patients with Attention-Deficit/Hyperactivity Disorder
2013 · Ling Jin, Wen Xu, et al. · Journal of Child and Adolescent Psychopharmacology · 10
Effect of lersivirine co-administration on pharmacokinetics of methadone in healthy volunteers
2012 · Manoli Vourvahis, Rong Wang, et al. · Drug and Alcohol Dependence · 10
1189 Gs-9669, a Novel Ns5b Non-nucleotide Site Ii Inhibitor, Demonstrates Potent Antiviral Activity, Favorable Safety Profile and Potential for Once-daily Dosing
2012 · E. Lawitz, L. Hazan, et al. · Journal of Hepatology · 9
847 Ach-2684 Demonstrates Potent Viral Suppression in Genotype 1 Hepatitis C Patients With and Without Cirrhosis: Safety, Pharmacokinetic, and Viral Kinetic Analysis
2013 · E. Lawitz, J. Hill, et al. · Journal of Hepatology · 5
PDF
Safety and Pharmacodynamics of Oral TLR-7 agonist GS-9620 in patients with Chronic Hepatitis B
2013 · Edward Gane, Éric Sicard, et al. · Hepatology · 4
Dietary vitamin B12 deficiency in a patient with multiple sclerosis
1994 · Daniel M. Gruener, Elisabeth J. Shakin Kunkel, et al. · General Hospital Psychiatry · 4
S43. a Proof-of-mechanism Study of the Pde10 Inhibitor Rg7203 in Patients With Probing Reward Functions With Imaging and Behavioral Approaches
2018 · Daniel Umbricht, Jürgen Dukart, et al. · Schizophrenia Bulletin · 2
1206 Pharmacodynamics of Oral Tlr-7 Agonist Gs-9620 in Treatment-naive Patients With Chronic Hepatitis C
2013 · E. Lawitz, D. Gruener, et al. · Journal of Hepatology
PDF
Works count: 19
Citation count: 561
H-index: 11
I10-index: 13
Year
Topic
Type